Drug Trial Radar · NCT04627025
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
164
Actual
Start
Jan 26, 2021
Primary completion
Jan 2, 2024
Study completion Feb 22, 2024
Sponsor
- Lead sponsor
- VectivBio AGIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.
Conditions
- Short Bowel Syndrome
Interventions
apraglutideDrug
Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change from baseline in actual weekly PS volume at Week 24.Time frame: At week 24 of treatment
Locations
68 sites in 18 countries. Site status is shown where the registry gives one.
Ronald Reagan UCLA Medical Center
Los Angeles, California
Gastroenterology Group of Naples
Naples, Florida
Northwestern University
Chicago, Illinois
Henry Ford Medical Center - Columbus
Novi, Michigan
Mayo Clinic
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Mount Sinai Medical Center
New York, New York
Duke University Hospital
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University Medical Center, Center for Human Nutrition
Nashville, Tennessee
University of Washington Medical Center
Seattle, Washington
University Hospital Foundation Favaloro
Buenos Aires, Argentina
University Hospital Brussels
Brussels, Belgium
Universitair Ziekenhuis Leuven - Gasthuisberg
Leuven, Vlaams Brabant, Belgium
University Hospital Brno
Brno, Czechia
University Hospital Hradec Kralove
Hradec Králové, Czechia
Hospital Novy Jicin
Nový Jičín, Czechia
University Hospital Plzen
Pilsen, Czechia
University Hospital Kralovske Vinohrady, 2nd Internal Clinic
Prague, Czechia
General University Hospital in Prague
Prague, Czechia
Rigshospitalet - University Hospital Copenhagen
Copenhagen, Denmark
Hôpital Beaujon
Clichy, France
CHU Hôtel Dieu
Nantes, France
Hôpital ARCHET II
Nice, France
Hôpital Haut-Lévèque
Pessac, France
Hospices Civils de Lyon
Pierre-Bénite, France
Brabois Adults Hospital
Vandœuvre-lès-Nancy, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
University Hospital Bonn
Bonn, Germany
Asklepios Klinik St. Georg
Hamburg, Germany
University Hospital Heidelberg
Heidelberg, Germany
University Hospital Muenster
Münster, Germany
Medical Centre, Hungarian Defence Forces
Budapest, Hungary
Semmelweis University
Budapest, Hungary
St. Imre University Teaching Hospital Budapest
Budapest, Hungary
University of Szeged
Szeged, Hungary
Rambam Health Care Campus
Haifa, Israel
Rabin Medical Center
Petah Tikva, Israel
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.